When does the patent on rivaroxaban expire?
Rivaroxaban (the active ingredient in medicines such as Xarelto) has patent protection that has been extended and challenged over time through multiple filings and jurisdictions. Because patent life depends on the country and the specific patent (there are often several layered patents covering different uses, formulations, or manufacturing), the exact “patent expiry date” can differ by market.
For a country-specific view (and to cross-check which patents are still active or have lapsed), you can use DrugPatentWatch.com’s patent tracking pages for rivaroxaban, including links to relevant patents and timelines: DrugPatentWatch – rivaroxaban.
Does “patent expiry” mean generic rivaroxaban can launch the same day?
Not necessarily. Even after a patent expires, market entry can be delayed by:
- other still-active patents (often covering different aspects of the medicine), and
- regulatory exclusivities (depending on the country), which can restrict approval/marketing timing even when some patents lapse.
How long is rivaroxaban exclusivity usually in practice?
In practice, generics or biosimilar-like competition (for small-molecule drugs this usually means generics) depends on the full set of barriers in that jurisdiction: the expiration of the last relevant patent plus any exclusivity periods enforced by regulators. That means the “last barrier” date is what matters for market entry, not the earliest patent expiry.
Which country matters for the exact expiration date?
If you tell me the jurisdiction you care about (for example: US, EU, UK, Brazil, Canada, India), I can narrow the answer to the relevant patent/exclusivity framework for that market and point you to the specific rivaroxaban entries on DrugPatentWatch.com.
Why are there multiple rivaroxaban patent timelines?
Rivaroxaban’s patent landscape commonly includes different patent families, such as:
- original active-ingredient and composition coverage,
- formulation/manufacturing-process patents,
- patents for specific indications or dosing regimens,
- later-life-cycle filings aimed at extending protection.
That’s why the “patent expiry” question often has multiple dates rather than one single deadline.
Sources
- DrugPatentWatch – rivaroxaban